Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$13.78 +1.49%

+$0.37 today

Market cap
$1.22B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.39M

Average 1.48M

MLYS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

No reported Gross Margin figures are available to summarize.

Gross Margin history

Percent of revenue · from the income statement

No Gross Margin data reported for this period type.

Gross Margin vs competitors

How MLYS compares with its peers on the latest reported figures

MLYS Competitors Peer median
Gross Margin for MLYS and competitors
Company Period LTM level YoY 3-year change
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
TVTXTravere Therapeutics, Inc.LTM Sep 202660.7% -37.0 pp+1.9 pp
MLYSMineralys Therapeutics, Inc.FY2025— ——
VERAVera Therapeutics, Inc.FY2025— ——
DMACDiaMedica Therapeutics Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
Peer median (excluding MLYS) 92.0%-8.0 pp+5.2 pp

Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development16.31M26.25M70.36M168.58M132.01M
Selling, General & Admin2.42M5.23M14.3M23.82M38.6M
Operating Expenses18.73M31.48M84.66M192.4M170.6M
Depreciation & Amortization00043K59K
EBITDA(19.38M)(28.12M)(71.9M)(177.77M)(154.59M)
EBITDA Margin—————
Operating Income(18.73M)(31.48M)(84.66M)(192.4M)(170.6M)
Operating Margin—————
Interest Income01.68M12.76M14.59M15.95M
Interest Expense27K1.68M000
Other Income / Expenses(683K)1.68M12.76M14.59M15.95M
Income Before Tax(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Net Margin—————
EPS (Basic)(3.89)(5.77)(1.99)(3.66)(2.29)
EPS (Diluted)(3.89)(5.77)(1.99)(3.66)(2.29)
Weighted Avg Shares4.98M5.17M36.19M48.54M67.66M
Weighted Avg Shares (Diluted)4.98M5.17M36.19M48.54M67.66M

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Intrinsic Alpha fair value

Locked

Current Price

$13.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.